Conclusion
tumor, mutated melanoma
TUMOR
These recent clinical trials have explored several aspects of sequencing and combining the principle therapeutic approaches for BRAF mutated melanoma. The sponsors and the investigators must be congratulated for this network of sophisticated clinical trials that have included more than 1200 patients. The result is decent evidence that starting with immunotherapy first is the appropriate strategy. In patients that need immediate tumor reduction, a short-term use of targeted therapy might be considered with a switch to combination immunotherapy after 8 to 12 weeks. Some of us have expected another outcome, but this is the justification of clinical research: generate evidence instead of gut feeling!